About
Antibody-Oligonucleotide Treatments for Muscle Diseases
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBoston & New England
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
2
As Collaborator
3
Total Enrollment
1,020
By Phase
PHASE1: 1PHASE1/PHASE2: 2
By Status
RECRUITING: 3COMPLETED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06014853Collaborator
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects
PHASE1Completed
48 participants
Started: Aug 10, 2023 · Completed: Nov 16, 2023
NCT05481879Lead Sponsor
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
PHASE1/PHASE2Recruiting
116 participants
Started: Sep 5, 2022 · Completed: Jul 31, 2029
NCT05524883Lead Sponsor
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
PHASE1/PHASE2Active, not recruiting
86 participants
Started: Aug 12, 2022 · Completed: Nov 30, 2029
NCT04635891Collaborator
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
N/ARecruiting
450 participants
Started: Dec 15, 2020 · Completed: Jan 31, 2028
NCT03458832Collaborator
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
N/ARecruiting
320 participants
Started: Mar 5, 2018 · Completed: Dec 31, 2027
Locations (1)
Headquarters
Waltham, MA, United States
Map
Loading map...